Astrana Health Inc

ASTH is in a Stage 3 distribution phase with active support failures and a clear lower-high/lower-low sequence. Price has broken below the 9EMA/20EMA resistance zone on expanding down-volume, confirming medium-term bearish bias. Short-term momentum is rolling over with price rejecting at short EMAs, offering a tactically favorable environment to sell into weakness. The Value + EPS strategy aligns with selective execution on structural breakdowns and resistance rejections.

• ↑Q1 revenue jumped 56% YoY to $965.1 M, driven by value-based care
• ↑40% of members in full-risk contracts now, providing 80% of Care Partners revenue
• ↓Negative profitability factors indicate potential margin pressure as contracts mature